Published in Cancer Immunol Immunother on September 18, 2002
Matrix metalloproteinase-2 conditions human dendritic cells to prime inflammatory T(H)2 cells via an IL-12- and OX40L-dependent pathway. Cancer Cell (2011) 1.22
MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency. J Exp Med (2008) 1.13
alpha v beta3-dependent cross-presentation of matrix metalloproteinase-2 by melanoma cells gives rise to a new tumor antigen. J Exp Med (2005) 0.90
Optimum in vitro expansion of human antigen-specific CD8 T cells for adoptive transfer therapy. Clin Exp Immunol (2005) 0.87
Perioperative cimetidine administration promotes peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with gastrointestinal cancer: Results of a randomized controlled clinical trial. World J Gastroenterol (2004) 0.82
Comparison of three culture media for the establishment of melanoma cell lines. Cytotechnology (2010) 0.81
Value of large scale expansion of tumor infiltrating lymphocytes in a compartmentalised gas-permeable bag: interests for adoptive immunotherapy. J Transl Med (2011) 0.80
Adoptive TIL transfer in the adjuvant setting for melanoma: long-term patient survival. J Immunol Res (2014) 0.80
Telomerase and primary T cells: biology and immortalization for adoptive immunotherapy. Immunotherapy (2011) 0.80
Tissue biomarkers in melanoma patients treated with TIL. PLoS One (2012) 0.79
What's the place of immunotherapy in malignant mesothelioma treatments? Cell Adh Migr (2010) 0.78
Expression of co-stimulator 4-1BB molecule in hepatocellular carcinoma and adjacent non-tumor liver tissue, and its possible role in tumor immunity. World J Gastroenterol (2004) 0.77
A full GMP process to select and amplify epitope-specific T lymphocytes for adoptive immunotherapy of metastatic melanoma. Clin Dev Immunol (2013) 0.77
Summit on cell therapy for cancer: The importance of the interaction of multiple disciplines to advance clinical therapy. J Transl Med (2011) 0.75
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med (2014) 5.43
Identification of SLC39A4, a gene involved in acrodermatitis enteropathica. Nat Genet (2002) 2.29
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol (2009) 2.28
Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones. J Invest Dermatol (2009) 1.87
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer (2005) 1.55
Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome. Arch Dermatol (2008) 1.47
V gamma 9V delta 2 T cell response to colon carcinoma cells. J Immunol (2005) 1.45
Hidradenitis suppurativa and zinc: a new therapeutic approach. A pilot study. Dermatology (2007) 1.41
Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol (2005) 1.30
The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion. PLoS One (2012) 1.23
Matrix metalloproteinase-2 conditions human dendritic cells to prime inflammatory T(H)2 cells via an IL-12- and OX40L-dependent pathway. Cancer Cell (2011) 1.22
An update on mutations of the SLC39A4 gene in acrodermatitis enteropathica. Hum Mutat (2009) 1.20
Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. J Immunol (2006) 1.20
Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells. J Immunol (2005) 1.13
MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency. J Exp Med (2008) 1.13
Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother (2002) 1.12
Long-lasting cross-presentation of tumor antigen in human DC. Eur J Immunol (2009) 1.09
Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen. J Immunol (2003) 1.07
Dominant TCR V alpha usage by virus and tumor-reactive T cells with wide affinity ranges for their specific antigens. Eur J Immunol (2002) 1.07
Living with acne. A study of adolescents' personal experiences. Dermatology (2007) 1.07
Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. J Immunol (2003) 1.05
Unique functional status of natural killer cells in metastatic stage IV melanoma patients and its modulation by chemotherapy. Clin Cancer Res (2011) 1.03
Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer (2008) 1.03
HLA-E/β2 microglobulin overexpression in colorectal cancer is associated with recruitment of inhibitory immune cells and tumor progression. Int J Cancer (2012) 1.00
A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion. J Immunol (2002) 0.99
Acne as seen by adolescents: results of questionnaire study in 852 French individuals. Acta Derm Venereol (2011) 0.97
Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother (2007) 0.95
Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients. Cancer Immunol Immunother (2006) 0.94
Infantile acne: a retrospective study of 16 cases. Pediatr Dermatol (2008) 0.94
Sudden onset of an aggressive cutaneous lymphoma in a young patient with psoriasis: role of immunosuppressants. Acta Derm Venereol (2010) 0.93
In vitro modulation of TLR-2, CD1d and IL-10 by adapalene on normal human skin and acne inflammatory lesions. Exp Dermatol (2007) 0.92
Hidradenitis suppurativa: the role of deficient cutaneous innate immunity. Arch Dermatol (2011) 0.92
ERK-regulated differential expression of the Mitf 6a/b splicing isoforms in melanoma. Pigment Cell Melanoma Res (2009) 0.91
Urotensin II is a new chemotactic factor for UT receptor-expressing monocytes. J Immunol (2007) 0.91
alpha v beta3-dependent cross-presentation of matrix metalloproteinase-2 by melanoma cells gives rise to a new tumor antigen. J Exp Med (2005) 0.90
Zinc salts inhibit in vitro Toll-like receptor 2 surface expression by keratinocytes. Eur J Dermatol (2007) 0.90
Apoptotic body-loaded dendritic cells efficiently cross-prime cytotoxic T lymphocytes specific for NA17-A antigen but not for Melan-A/MART-1 antigen. Int J Cancer (2002) 0.89
A fast and efficient HLA multimer-based sorting procedure that induces little apoptosis to isolate clinical grade human tumor specific T lymphocytes. Cancer Immunol Immunother (2008) 0.89
Combined 0.1% retinaldehyde/ 6% glycolic acid cream in prophylaxis and treatment of acne scarring. Dermatology (2007) 0.88
Mutation spectrum of human SLC39A4 in a panel of patients with acrodermatitis enteropathica. Hum Mutat (2003) 0.88
Frequent occurrence of high affinity T cells against MELOE-1 makes this antigen an attractive target for melanoma immunotherapy. Eur J Immunol (2010) 0.88
Acne counseling to improve adherence. Cutis (2008) 0.88
Prognostic value of tumor-infiltrating Foxp3+ T-cell subpopulations in metastatic melanoma. Exp Dermatol (2011) 0.87
Treatment of a multicentric Merkel cell carcinoma using imatinib. Eur J Dermatol (2012) 0.87
Synthetic anticancer vaccine candidates: rational design of antigenic peptide mimetics that activate tumor-specific T-cells. J Med Chem (2007) 0.86
Expression of CD94/NKG2-A on human T lymphocytes is induced by IL-12: implications for adoptive immunotherapy. J Immunol (2002) 0.86
Identification of two Melan-A CD4+ T cell epitopes presented by frequently expressed MHC class II alleles. Clin Immunol (2006) 0.86
Serum soluble HLA-E in melanoma: a new potential immune-related marker in cancer. PLoS One (2011) 0.86
HLA anchor optimization of the melan-A-HLA-A2 epitope within a long peptide is required for efficient cross-priming of human tumor-reactive T cells. J Immunol (2012) 0.85
PBMC are as good a source of tumor-reactive T lymphocytes as TIL after selection by Melan-A/A2 multimer immunomagnetic sorting. Cancer Immunol Immunother (2007) 0.85
Different strains of Propionibacterium acnes modulate differently the cutaneous innate immunity. Exp Dermatol (2013) 0.85
In vitro induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 expression in keratinocytes by boron and manganese. Exp Dermatol (2004) 0.84
Tumor-reactive CD4+ CD8αβ+ CD103+ αβT cells: a prevalent tumor-reactive T-cell subset in metastatic colorectal cancers. Int J Cancer (2010) 0.84
Increased frequency of nonconventional double positive CD4CD8 alphabeta T cells in human breast pleural effusions. Int J Cancer (2009) 0.84
TLR expression in human melanoma cells. Eur J Dermatol (2012) 0.84
Physiopathology of acne vulgaris: recent data, new understanding of the treatments. Eur J Dermatol (2004) 0.84
Tissue prognostic markers for adoptive immunotherapy in melanoma. Eur J Dermatol (2007) 0.84
Development of an individual score for melanoma risk. Eur J Cancer Prev (2011) 0.83
Melanoma incidence and patient compliance in a targeted melanoma screening intervention. One-year follow-up in a large French cohort of high-risk patients. Eur J Gen Pract (2014) 0.83
Anti-inflammatory effects of lithium gluconate on keratinocytes: a possible explanation for efficiency in seborrhoeic dermatitis. Arch Dermatol Res (2008) 0.83
Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing interferon-γ) in metastatic melanoma patients. Cancer Immunol Immunother (2015) 0.83
Fetal fibroblasts and keratinocytes with immunosuppressive properties for allogeneic cell-based wound therapy. PLoS One (2013) 0.83
Inducible Hsp70 as target of anticancer immunotherapy: Identification of HLA-A*0201-restricted epitopes. Int J Cancer (2004) 0.82
Double positive CD4CD8 alphabeta T cells: a new tumor-reactive population in human melanomas. PLoS One (2010) 0.82
About the cutaneous targets of bexarotene in CTCL patients. Exp Dermatol (2010) 0.82
A spliced antigenic peptide comprising a single spliced amino acid is produced in the proteasome by reverse splicing of a longer peptide fragment followed by trimming. J Immunol (2014) 0.82